不可切除胰臟癌患者常因難以控制、持續且令人喪失能力的疼痛而感到沮喪。此疼痛必須積極處理，並建議以強效鴉片類藥物作為主要治療。然而，患者會出現鴉片類藥物相關不良事件。EUS 引導的腹腔神經叢阻斷術（CPN）及腹腔神經節阻斷術（CGN）已顯示對疼痛控制具有高效能。然而，最佳時機仍存在爭議。
適應症：Pancreatic Cancer Non-resectable、Tumor Pancreas、Pain Cancer
收案條件
納入條件
- Age \>= 18 years old
- Diagnosed to have inoperable pancreatic cancer
- Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS \>= 3
- Karnofsky performance status \>= 60
- Planned for EUS examination and/or biopsy of the pancreatic tumor
排除條件
- Allergy to bupivacaine, or alcohol
- Potentially operable after neoadjuvant therapy
- Expected survival of less than 3 months
- Patient who is already on opioids for pain control
- Previous percutaneous or EUS-guided CGN/ CPN
- Recurrent pancreatic tumors after operation
- Uncorrectable coagulopathy
- Inability or unwillingness to provide informed consent
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。